Kefauver–Harris Amendment
Senate Judiciary Committee on October 10, 1962 |
The U.S. Kefauver–Harris Amendment or "Drug Efficacy Amendment" is a 1962 amendment to the Federal Food, Drug, and Cosmetic Act.
It introduced a requirement for drug manufacturers to provide proof of the effectiveness and safety of their drugs before approval,[1][2] required drug advertising to disclose accurate information about side effects, and stopped cheap generic drugs being marketed as expensive drugs under new trade names as new "breakthrough" medications.
Background
The amendment was a response to the
It introduced a "proof-of-efficacy" requirement for the first time.[1] In addition, the Amendment required drug advertising to disclose accurate information about side effects and efficacy of treatments. Finally, cheap generic drugs could no longer be marketed as expensive drugs under new trade names as new "breakthrough" medications.
The law was signed by President John F. Kennedy on October 10, 1962.
Effect
The Kefauver–Harris Amendment strengthened the
The Drug Efficacy Study Implementation was begun to classify all pre-1962 drugs that were already on the market as either effective, ineffective, or needing further study.
Estes Kefauver considered the Amendment his "finest achievement" in consumer protection.[citation needed]
Louis Lasagna, then a prominent clinical pharmacologist at the Johns Hopkins School of Medicine, advised Congress about the proper conduct of clinical research during the 1962 hearings leading up to passage of the Amendment.
The law also exempted from the "
See also
- Criticism of the FDA
- Directive 65/65/EEC1(Europe)
- Drug Efficacy Study Implementation
- Durham-Humphrey Amendment
- Federal Food, Drug, and Cosmetic Act
- Frances Oldham Kelsey
- Regulation of therapeutic goods
References
- ^ a b Peltzman, Sam. An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments. The Journal of Political Economy, Vol. 81, No. 5. (Sep. - Oct., 1973), pp. 1051.
- ^ "Promoting Safe and Effective Drugs for 100 Years". The Kefauver-Harris Drug Amendments. U.S. Food and Drug Administration.
- ^ O'Reilly, James, Jurisdiction to Decide an Agency's Own Jurisdiction: The Forgotten Tale of the Hynson Quartet, Administrative Law Review, Vol. 58, No. 4 (Fall 2006), pp. 829-843 (15 pages).
- ^ "Kefauver-Harris Amendments Revolutionized Drug Development". www.fda.gov. Archived from the original on 2019-05-07.
- PMID 14076167.
Sources
- Abood, R.R., & Brushwood, D.B. (1994). Pharmacy practice and the law. Gaithersburg, MD: Aspen Publishers, Inc.
- Krantz JC Jr., New Drugs and the Kefauver–Harris Amendment, J New Drugs, 1966, Mar-Apr;6(22):77-9
- Krantz JC Jr., The Kefauver-Harris amendment after sixteen years, Mil Med. 1978 Dec;143(12):883.
External links
- 50 Years: The Kefauver-Harris Amendments from the U.S. Food and Drug Administration
- Drug Amendments Act of 1962, Enrolled Acts and Resolutions of Congress at the U.S. National Archives and Records Administration